Hot Features
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug D... TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.08 | -2.46153846154 | 3.25 | 3.68 | 3.0504 | 258217 | 3.3988764 | CS |
| 4 | -1.25 | -28.2805429864 | 4.42 | 4.73 | 2.2 | 825921 | 2.87059682 | CS |
| 12 | -0.96 | -23.2445520581 | 4.13 | 4.8499 | 2.2 | 371035 | 3.2225366 | CS |
| 26 | -3.615 | -53.2792925571 | 6.785 | 7.95 | 2.2 | 273816 | 4.1789934 | CS |
| 52 | -1.94 | -37.9647749511 | 5.11 | 7.95 | 2.2 | 195058 | 4.43402233 | CS |
| 156 | -10.63 | -77.0289855072 | 13.8 | 16.24 | 2.2 | 99526 | 5.01164798 | CS |
| 260 | -10.63 | -77.0289855072 | 13.8 | 16.24 | 2.2 | 99526 | 5.01164798 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.